We opened account creation again last month. Welcome to all new users, and thank you for your support! We are now in a situation where we have a number of new models for which we are currently estimating model parameters, and therefore can make good use of you contribution.


In July, we sent out the last in a series of runs to do with two potential malaria control strategies under evaluation: intermittent preventive treatment in infants (IPTi) and in children (IPTc). They involve giving a treatment dose of an anti-malarial drug at either pre-specified ages or calendar times. The aim is to reduce the burden of clinical malaria episodes and deaths without incurring problems with sustainability, drug resistance or preventing the child from gaining acquired immunity. Field trials so far have shown encouraging results and there is evidence that choosing a drug with a long half-life is important for protection.

We are interested in looking at where these strategies might be useful and cost-effective. The workunits you have been running look at a bunch of different variables: delivery strategies, drug characteristics, levels of drug resistance already present in the locations, levels of transmission, the seasonal pattern of malaria transmission, the health system coverage for effective treatment of clinical cases and varying health system costs. They are nearly complete � many thanks! We are looking forward to analysing the results.

Amanda
Project scientist

We opened account creation again last month. Welcome to all new users, and thank you for your support! We are now in a situation where we have a number of new models for which we are currently estimating model parameters, and therefore can make good use of you contribution.


In July, we sent out the last in a series of runs to do with two potential malaria control strategies under evaluation: intermittent preventive treatment in infants (IPTi) and in children (IPTc). They involve giving a treatment dose of an anti-malarial drug at either pre-specified ages or calendar times. The aim is to reduce the burden of clinical malaria episodes and deaths without incurring problems with sustainability, drug resistance or preventing the child from gaining acquired immunity. Field trials so far have shown encouraging results and there is evidence that choosing a drug with a long half-life is important for protection.

We are interested in looking at where these strategies might be useful and cost-effective. The workunits you have been running look at a bunch of different variables: delivery strategies, drug characteristics, levels of drug resistance already present in the locations, levels of transmission, the seasonal pattern of malaria transmission, the health system coverage for effective treatment of clinical cases and varying health system costs. They are nearly complete � many thanks! We are looking forward to analysing the results.

Amanda
Project scientist

What kind of data is being processed at the moment? Please keep uo your monthly updates here in the forum. It is apreciated very much.